Albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
The use of high-resolution ion-mobility mass spectrometry (IMS-MS) on HPLC-purified alpha-synuclein in vitro has shown alpha-synuclein to be autoproteolytic (self-proteolytic), generating a variety of small molecular weight fragments upon incubation. The 14.46 kDa protein was found to generate numerous smaller fragments, including 12.16 kDa (amino acids 14–133) and 10.44 kDa (40–140) fragments formed through C- and N-terminal truncation and a 7.27 kDa C-terminal fragment (72–140). The 7.27 kDa fragment, which contains the majority of the NAC region, aggregated considerably faster than full-length alpha-synuclein. It is possible that these autoproteolytic products play a role as intermediates or cofactors in the aggregation of alpha-synuclein in vivo.
Tbr1 forms a complex with CASK and regulates gene expression in cortical development. Tbr1 binds to the guanylate kinase (GK) domain of CASK. It was determined that the C-terminal domain of Tbr1 in crucial and solely capable of this process. Through luciferase reporter assays of neurons in the hippocampus, it was found that increased Tbr1/CASK complex expression results in enhanced promoter activity in genes downstream of TBR1 such as NMDAR subunit 2b (NMDAR2b), glycine transporter, interleukin-7 receptor (IL-7R) and OX-2 genes. NMDAR2b experienced the greatest change in activity. Tbr1 and CASK also play an important role in activation of the RELN gene. One study suggests that CASK acts as a coactivator of TBR1, interacting with CINAP (CASK-interacting nucleosome assembly protein) to form a complex with Tbr1. The Tbr1/CASK/CINAP complex regulates expression of NMDAR2b and RELN, which both play important roles in long-term potentiation. Sox5 is another co-regulatory protein of Tbr1. Sox5 is a marker of layer VI neurons in the neocortex. It aids in the suppression of layer V neuron identity within layer VI cortical neurons through suppression of Fezf2. TBR1 is involved in the downstream regulation of Sox5. Sox5 expression was reduced in Tbr1 null mutants. It has been found that Sox5 interacts with Tbr1 to regulate Fezf2 transcription in layer VI cortical neurons.
An added advantage of the prussian blue is that the caesium which is stripped from the animal in the droppings is in a form which is not available to plants. Hence it prevents the caesium from being recycled. The form of prussian blue required for the treatment of animals, including humans is a special grade. Attempts to use the pigment grade used in paints have not been successful.
== Contraindications == Under the US approval, ertugliflozin is contraindicated for people with severe kidney failure, end-stage renal disease, and dialysis. The European Union approval does not list any contraindications apart from hypersensitivity to the drug, which is standard for all drug approvals.
Sources: en.wikipedia.org
== History == The original Landspítali began operations on 20 December 1930. Ideas for a hospital that served the whole country was not new; in 1863, Jón Hjaltalín, the then Director of Health, proposed a bill that would establish such a hospital, but the bill was not voted on. During the period from 1863 to 1930, several hospitals operated in Reykjavík. The founding of Landspítali was the product of a long, hard struggle in which women were at the forefront and have ever since played a huge role in the country's hospital matters. In 2000, the Reykjavik City Hospital merged with Landspítali, and the new merged hospital was renamed as Landspítali University Hospital (Landspítali háskólasjúkrahús; LSH) until it reverted to its original name in 2007.
Racecadotril is rapidly absorbed after oral administration and reaches Cmax within 60 minutes. Food delays Cmax by 60 to 90 minutes but does not affect the overall bioavailability. Racecadotril is rapidly and effectively metabolized to the moderately active S-acetylthiorphan the main active metabolite thiorphan, of which 90% are bound to blood plasma proteins. In therapeutic doses, racecadotril does not pass the blood–brain barrier. Inhibition of enkephalinases starts 30 minutes after administration, reaches its maximum (75–90% inhibition with a therapeutic dose) two hours after administration, and lasts for eight hours. The elimination half-life, measured from enkephalinase inhibition, is three hours. Thiorphan is further metabolized to inactive metabolites such as the methyl thioether and the methyl sulfoxide. Both active and inactive metabolites are excreted, mostly via the kidney (81.4%), and to a lesser extent via the feces (8%).
=== Vaccine carriers === Vaccine carriers are similar to cold boxes, but they are smaller and easier to carry around. This small carrier is also packed with ice packs to keep the vaccine at a low temperature. However, they do not stay cold for as long as cold boxes, at most 36–48 hours. It is generally used for transporting from a health facility to outreach sites.
A compartment kiln is filled with a static batch of timber through which air is circulated. In these types of kiln, the timber remains stationary. The drying conditions are successively varied according to the type of timber being dried. This drying method is well suited to the needs of timber companies, which have to dry timbers of varied species and thickness, including refractory hardwoods that are more liable than other species to check and split. The main elements of chamber drying are:
=== Hard and soft ultraviolet === Some sources use the distinction of "hard UV" and "soft UV". For instance, in the case of astrophysics, the boundary may be at the Lyman limit (wavelength 91.2 nm, the energy needed to ionise a hydrogen atom from its ground state), with "hard UV" being more energetic; the same terms may also be used in other fields, such as cosmetology, optoelectronic, etc. The numerical values of the boundary between hard/soft, even within similar scientific fields, do not necessarily coincide; for example, one applied-physics publication used a boundary of 190 nm between hard and soft UV regions.
Sources: en.wikipedia.org
== Product quality controversy == During the 2008 Chinese milk scandal, Unilever recalled its Lipton milk tea powder in Hong Kong and Macau, after the company's internal checks found traces of melamine in the powder. In November 2011, the General Administration of Quality Supervision, Inspection and Quarantine of China found high levels of pesticides such as bifenthrin in one variety of Lipton tea. Unilever responded by clearing the shelves of all affected products. In April 2012, Greenpeace raised further questions about Lipton products in China, after two varieties of Lipton tea the group purchased in Beijing supermarkets failed safety tests, with the results allegedly failing to meet the regulations enforced in the European Union. The group also stated, "Some of the detected pesticides are also banned for use in tea production by the Chinese Ministry of Agriculture." Unilever China denied the findings, stating all Lipton products within the country were safe.
=== Amateur === Lisa has been weight training since 2003 and has been conditioning for competitive entry since 2008. She first really got into bodybuilding in 2006 while she was living in Japan while she was teaching English. Her boyfriend at the time was a Japanese bodybuilding champion and she started reading up on bodybuilding, such as Negrita Jayde, and started training with weights. In 2007, after she got married, she went to see the 2007 Ms. Olympia competition for their honeymoon and was impressed when she saw female bodybuilders for the first time. Former UK junior champion Lewis Breed oversees her training and pre-contest preparation for bodybuilding. She competed in her debut competition at the 2009 NABBA England, placing second place behind Jennie Ellam. She then competed at the 2009 NABBA Universe achieving second place to Larissa Cunha. Her best win was first place at the UKBFF British Championships, where she won the Ladies Physique class. On 19 March 2014, she announced that she had been awarded her IFBB pro card and can now compete as a pro.
== Evolution == It is believed that moonlighting proteins came about by means of evolution through which uni-functional proteins gained the ability to perform multiple functions. With alterations, much of the protein's unused space can provide new functions. Many moonlighting proteins are the result of the gene fusion of two single function genes. Alternatively a single gene can acquire a second function since the active site of the encoded protein typically is small compared to the overall size of the protein leaving considerable room to accommodate a second functional site. In yet a third alternative, the same active site can acquire a second function through mutations of the active site. The development of moonlighting proteins may be evolutionarily favorable to the organism since a single protein can do the job of multiple proteins conserving amino acids and energy required to synthesize these proteins. However, there is no universally agreed upon theory that explains why proteins with multiple roles evolved. While using one protein to perform multiple roles seems advantageous because it keeps the genome small, we can conclude that this is probably not the reason for moonlighting because of the large amount of noncoding DNA.
extensive property A physical quantity whose value is proportional to the size of the system it describes or to the quantity of matter in the system. Examples include mass, volume, enthalpy, and entropy. Contrast intensive property.
In practice, 48 states and the District of Columbia require their electors to vote for the statewide popular-vote winner; Maine and Nebraska award two votes to the statewide winner and one to the winner in each congressional district. Both the president and the vice president serve a four-year term, and the president may be reelected to the office only once, for one additional four-year term.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.